News

Algorae Pharmaceuticals has appointed Troy Valentine as a Non-Executive Director, a move the company says will materially deepen its board capability in capital markets, life sciences governance and international listed-company leadership. 

Starpharma has launched a fully underwritten renounceable entitlement offer to raise approximately $32 million, strengthening its balance sheet and providing a pro forma cash balance of $44.5 million.

The minister's reference to the US and broader international pressures belies the reality that the situation currently confronting MS patients relates to the demanded price reduction triggered by Australia's domestic policies.

Sydney-based Viral Vector Manufacturing Facility and Melbourne-headquartered Mirugen have signed a non-exclusive Letter of Intent to evaluate and potentially develop the company's AAV-based gene therapy candidate targeting Retinitis Pigmentosa.

The Parliamentary Budget Office’s 2026–27 Medium‑Term Budget Outlook paints a cautious picture for health, disability and medicines spending, with doubts over the budgeted savings for the National Disability Insurance Scheme.

As the Australian Government approaches negotiations with Medicines Australia and the Generic and Biosimilar Medicines Association for new agreements, the organisation says it is not acceptable to exclude patients, as it has in the past.

Thirteen representatives from government, industry, clinical care, research and patient advocacy met to identify practical actions to strengthen Australia’s paediatric oncology clinical trial ecosystem and attract greater investment so children and young people can access innovative therapies.

“This isn't simply a cancer story. It's an equity story,” said Meredith Cummins, CEO of NeuroEndocrine Cancer Australia. “Where you live, how far you are from specialist care, and your socioeconomic circumstances are increasingly influencing outcomes for people diagnosed with neuroendocrine cancer.”

While Australia is debating whether to fund weight-loss medication for a group of very sick people, one American thought leader argues against rationing innovations that are having a profoundly positive impact on quality of life.

A trip through a US supermarket or large retail outlet often takes you past a bank, an optometrist, a pharmacy, and sometimes insurance counters. These shops in the US are generally larger and configured to offer these multiple services. Australian supermarkets are typically smaller, and recent retail trends indicate they are shrinking further as retailers optimise floor plans for high‑margin groceries. Simply slotting a pharmacy into that footprint is neither straightforward nor, in most cases, practical. 

The Pharmacy Guild of Australia has rejected the latest report from the Grattan Institute, arguing the analysis misunderstands the role of community pharmacies and risks undermining equitable access to medicines and primary care.

Immutep has reported mature overall survival data from the investigator‑initiated INSIGHT‑003 trial that it says offer a hopeful signal for eftilagimod alfa, known as efti, in first-line non‑squamous non‑small cell lung cancer (NSCLC).